| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 71,430 | 86,771 | 67,455 | 59,952 |
| Cost of sales | 42,498 | 28,302 | 38,477 | 56,664 |
| Research and development | 62,487 | 68,854 | 75,174 | 79,363 |
| Selling, general, and administrative | 38,949 | 36,143 | 34,555 | 37,699 |
| Depreciation and amortization | 8,539 | 8,918* | 9,007 | NaN |
| Restructuring charges | NaN | 18,014* | 5,143 | NaN |
| Total costs and expenses | 152,473 | 160,231 | 162,356 | 173,726 |
| Loss from operations | -81,043 | -73,460 | -94,901 | -113,774 |
| Interest and other income, net | 1,333 | 1,740 | 1,243 | 4,104 |
| Net loss before income taxes | -79,710 | -71,720 | -93,658 | -109,670 |
| Income tax benefit | -665 | 184 | -2,405 | 1,988 |
| Net loss | -79,045 | -71,904 | -91,253 | -111,658 |
| Basic EPS | -0.19 | -176.251 | -0.25 | -0.33 |
| Diluted EPS | -0.19 | -173.406 | NaN | -0.33 |
| Basic Average Shares | 418,511 | 407,964 | 364,037 | 334,511 |
| Diluted Average Shares | 418,511 | 414,656 | NaN | 334,511 |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)